Home > Insider Trading > Filing (0001209191-21-041032)

Filing Details

Accession Number:: 0001209191-21-041032
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2021-06-16 17:59:55
Reporting Period:: 2021-06-15

Accepted Time:: 2021-06-16 17:59:55
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1817713	Janux Therapeutics Inc.	JANX	()	DE

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1652901	Avalon Ventures Xi, L.p.	1134 Kline Street La Jolla CA 92037		No	No	Yes	No
1844550	Avalon Bioventures Spv I, L.p.	1134 Kline Street La Jolla CA 92037		No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2021-06-15	1,138,665	$0.00	1,330,815	No	4	C	Direct
Common Stock	Acquisiton	2021-06-15	2,382,191	$0.00	3,713,006	No	4	C	Direct
Common Stock	Acquisiton	2021-06-15	674,211	$0.00	4,387,217	No	4	C	Direct
Common Stock	Acquisiton	2021-06-15	2,696,843	$0.00	2,696,843	No	4	C	Indirect	See footnote
Common Stock	Acquisiton	2021-06-15	1,153,238	$0.00	3,850,081	No	4	C	Indirect	See footnote
Common Stock	Acquisiton	2021-06-15	629,411	$17.00	4,479,492	No	4	P	Indirect	See footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Direct
No	4	C	Direct
No	4	C	Direct
No	4	C	Indirect	See footnote
No	4	C	Indirect	See footnote
No	4	P	Indirect	See footnote

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series Seed Convertible Preferred Stock	Disposition	2021-06-15	888,888	$0.00	1,138,665	$0.00
Common Stock	Series Seed 2 Convertible Preferred Stock	Disposition	2021-06-15	1,859,634	$0.00	2,382,191	$0.00
Common Stock	Series A Convertible Preferred Stock	Disposition	2021-06-15	526,316	$0.00	674,211	$0.00
Common Stock	Series A Convertible Preferred Stock	Disposition	2021-06-15	2,105,264	$0.00	2,696,843	$0.00
Common Stock	Series B Convertible Preferred Stock	Disposition	2021-06-15	900,264	$0.00	1,153,238	$0.00

Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
No	4	C	Direct
No	4	C	Direct
No	4	C	Direct
No	4	C	Indirect
No	4	C	Indirect

Footnotes

Each share of Series Seed Convertible Preferred Stock, Series Seed 2 Convertible Preferred Stock, Series A Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") converted into 1.281 shares of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock had no expiration date.
The shares are directly held by Avalon Ventures XI, L.P. (Avalon Ventures). Avalon Ventures XI GP LLC (Avalon XI GP) is general partner of Avalon Ventures and may be deemed to have voting and investment power with respect to the shares held by Avalon Ventures. Kevin Kinsella, Richard Levandov, Braden Bohrmann and Jay Lichter, Ph.D. are managing members of Avalon XI GP. Mr. Kinsella, Mr. Levandov, Mr. Bohrmann and Dr. Lichter share voting and investment power with respect to the shares held by Avalon Ventures. Each of such individuals disclaims beneficial ownership of all shares held by Avalon Ventures except to the extent of each such individual's actual pecuniary interest therein, if any.
The shares are directly held by Avalon BioVentures SPV I, LP (ABV SPV). ABV SPV I GP LLC (ABV GP) is a general partner of ABV SPV and may be deemed to have voting and investment power with respect to the shares held by ABV SPV and as a result may be deemed to have beneficial ownership of such shares. Dr. Lichter and Tighe Reardon share voting and investment power with respect to the shares held by ABV SPV. Each of such individuals disclaims beneficial ownership of all shares held by ABV SPV except to the extent of each such individual's actual pecuniary interest therein, if any.
The shares were purchased in the Issuer's initial public offering.